Abstract: The present invention is to provide a medical composition for the treatment or prophylaxis of glaucoma which comprises a pyridylaminoacetic acid compound represented by the formula (1):
Description: more than 100 pages hence not be pasted
claims:1. A medical composition for treatment or prophylaxis of glaucoma which comprises pyridylaminoacetic acid compound represented by the formula (1): [Formula 1]
wherein R1, R2 and R3 each independently represent a hydrogen atom or a C1-C6 alkyl
group,
Y represents a bicyclic heteroaromatic ring group or group -Q1-Q2 each of which may
be substituted by a group(s) selected from the group consisting of a halogen atom, C1-C6
alkyl group, halogeno C1-C6 alkyl group, C1-C6 alkoxyl group, halogeno C1-C6 alkoxyl
group and C1-C6 alkylthio group,
wherein Q1 represents an arylene group or a 5- to 6-membered heteroarylene group, Q2 represents an aromatic group or 5- to 6-membered ring heterocyclic group each of which may be substituted by a group(s) selected from the group consisting of a halogen atom, hydroxyl group, C1-C6 alkyl group, halogeno C1-C6 alkyl group, C1-C6 alkoxyl group and halogeno C1-C6 alkoxyl group, Z represents an aromatic group or a 5- to 6-membered heteroaromatic ring group each of which may be substituted by a group(s) selected from the group consisting of a halogen atom, C1-C6 alkyl group, halogeno C1-C6 alkyl group, C1-C6 alkoxyl group and halogeno C1-C6 alkoxyl group, or a pharmaceutically acceptable salt thereof as an effective ingredient.
2. The medical composition according to Claim 1, wherein R2 and R3 each independently represent a hydrogen atom or a C1-C4 alkyl group.
3. The medical composition according to Claim 1 or 2, wherein Y represents a bicyclic heteroaromatic ring group or a group -Q1-Q2 each of which may be substituted by a group(s) selected from the group consisting of a halogen atom, C1-C4 alkyl group, halogeno C1-C4 alkyl group, C1-C4 alkoxyl group, halogeno C1-C4 alkoxyl group and
C1-C4 alkylthio group,
wherein Q1 represents an arylene group or a 5- to 6-membered heteroarylene group, Q2 represents an aromatic group or a 5- to 6-membered ring heterocyclic group each of which may be substituted by a group(s) selected from the group consisting of a halogen atom, hydroxyl group, C1-C4 alkyl group, halogeno C1-C4 alkyl group, C1-C4 alkoxyl group and halogeno C1-C4 alkoxyl group.
4. The medical composition according to any one of Claims 1 to 3, wherein Z repre-sents an aromatic group or a completely unsaturated 5- to 6-membered heteroaromatic ring group each of which may be substituted by a group(s) selected from the group consisting of a halogen atom, C1-C4 alkyl group, halogeno C1-C4 alkyl group, C1-C4 alkoxyl group and halogeno C1-C4 alkoxyl group.
5. The medical composition according to any one of Claims 1 to 4, wherein Y represents a benzofuryl group, benzothienyl group, benzoxazolyl group or benzo-thiazolyl group, or group -Q1-Q2 each of which may be substituted by a group(s) selected from the group consisting of a halogen atom, C1-C4 alkyl group, halogeno C1-C4 alkyl group, C1-C4 alkoxyl group, halogeno C1-C4 alkoxyl group and C1-C4 alkylthio group,
wherein Q1 represents a phenylene group, thienylene group, pyridazinylene group or pyrimidinylene group, Q2 represents a phenyl group, thienyl group, pyrazolyl group, oxazolyl group, thiazolyl group, 1,2,4-triazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, 4,5-dihydrothiazolyl group, pyrrolidinyl group or piperidinyl group which may be substituted by a group(s) selected from the group consisting of a halogen atom, hydroxyl group, C1-C4 alkyl group, halogeno C1-C4 alkyl group, C1-C4 alkoxyl group and halogeno C1-C4 alkoxyl group.
6. The medical composition according to Claim 5, wherein Y represents a benzofuryl
group, benzothienyl group, benzoxazolyl group or benzothiazolyl group each of which
may be substituted by a group(s) selected from the group consisting of a fluorine atom,
chlorine atom, bromine atom, methyl group, ethyl group, propyl group, isopropyl group,
tert-butyl group, trifluoromethyl group, difluoromethyl group, trichloromethyl group,
dichloromethyl group, 2,2,2-trifluoroethyl group, 2,2,2-trichloroethyl group, methoxy
group, ethoxy group, propoxy group, isopropoxy group, tert-butoxy group, trifluoro-
methoxy group, difluoromethoxy group, trichloromethoxy group, dichloromethoxy
group, methylthio group, ethylthio group, propylthio group, isopropylthio group and tert-butylthio group.
7. The medical composition according to Claim 5, wherein Y is a group -Q1-Q2
wherein Q1 represents a phenylene group, thienylene group, pyridazinylene group or pyrimidinylene group, Q2 represents a phenyl group, thienyl group, pyrazolyl group, oxazolyl group, thiazolyl group, 1,2,4-triazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, 4,5-dihydrothiazolyl group, pyrrolidinyl group or piperidinyl group each of which may be substituted by a group(s) selected from the group consisting of a fluorine atom, chlorine atom, bromine atom, hydroxyl group, methyl group, ethyl group, propyl group, isopropyl group, tert-butyl group, trifluoromethyl group, difluoromethyl group, trichloromethyl group, dichloromethyl group, 2,2,2-trifluoroethyl group, 2,2,2-trichloroethyl group, methoxy group, ethoxy group, propoxy group, isopropoxy group, tert-butoxy group, trifluoromethoxy group, difluoromethoxy group, trichloromethoxy group and dichloromethoxy group.
8. The medical composition according to any one of Claims 1 to 7, wherein Z repre-sents a phenyl group, thienyl group, imidazolyl group, thiazolyl group, pyridyl group or pyrimidinyl group each of which may be substituted by a group(s) selected from the group consisting of a halogen atom, C1-C4 alkyl group, halogeno C1-C4 alkyl group, C1-C4 alkoxyl group and halogeno C1-C4 alkoxyl group.
9. The medical composition according to Claim 8, wherein Z represents a phenyl group, thienyl group, imidazolyl group, thiazolyl group, pyridyl group or pyrimidinyl group each of which may be substituted by a group(s) selected from the group consist-ing of a fluorine atom, chlorine atom, bromine atom, methyl group, ethyl group, propyl group, isopropyl group, tert-butyl group, trifluoromethyl group, difluoromethyl group, trichloromethyl group, dichloromethyl group, 2,2,2-trifluoroethyl group, 2,2,2-trichloro-ethyl group, methoxy group, ethoxy group, propoxy group, isopropoxy group, tert-butoxy group, trifluoromethoxy group, difluoromethoxy group, trichloromethoxy group and dichloromethoxy group.
10. The medical composition according to any one of Claims 1 to 9, wherein R2 and
R3 each independently represent a hydrogen atom or a methyl group.
11. The medical composition according to any one of Claims 1 to 5 and 8 to 10, wherein Y represents a benzofuryl group or benzothienyl group each of which may be substituted by a group(s) selected from the group consisting of a halogen atom and a C1-C4 alkoxyl group.
12. The medical composition according to any one of Claims 1 to 5 and 8 to 10, wherein Y represents a group -Q1-Q2
wherein Q1 repersents a phenylene group or pyridazinylene group, Q2 represents a phenyl group, pyrazolyl group, thiazolyl group, 1,2,4-triazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group or 4,5-dihydrothiazolyl group each of which may be substituted by a group(s) selected from the group consisting of a halogen atom, C1-C4 alkyl group and halogeno C1-C4 alkyl group.
13. The medical composition according to any one of Claims 1 to 5 and 8 to 10, wherein Z represents a phenyl group or pyridyl group each of which may be substituted by a group(s) selected from the group consisting of a halogen atom and a C1-C4 alkoxyl group.
14. The medical composition according to Claim 1, wherein R1 represents a hydrogen atom, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group or hexyl group,
R2 and R3 each independently represent a hydrogen atom or methyl group, Y represents a benzofuran-2-yl group, 6-fluorobenzofuran-2-yl group, 6-chlorobenzo-furan-2-yl group, 6-methoxybenzofuran-2-yl group, benzo[b]thiophen-2-yl group, 6-fluorobenzo[b]thiophen-2-yl group, 5,6-difluorobenzo[b]thiophen-2-yl group, 6-chloro-benzo[b]thiophen-2-yl group, 6-chloro-5-fluorobenzo[b]thiophen-2-yl group, 6-methyl-benzo[b]thiophen-2-yl group, 5-fluoro-6-methylbenzo[b]thiophen-2-yl group, 6-ethyl-benzo[b]thiophen-2-yl group, 6-ethyl-5-fluorobenzo[b]thiophen-2-yl group, 6-trifluoro-methylbenzo[b]thiophen-2-yl group, 5-fluoro-6-trifluoromethylbenzo[b]thiophen-2-yl group, 6-methoxybenzo[b]thiophen-2-yl group, 5-fluoro-6-methoxybenzo[b]thiophen-2-yl group, 6-difluoromethoxybenzo[b]thiophen-2-yl group, 6-difluoromethoxy-5-fluoro-benzo[b]thiophen-2-yl group, 6-methylthiobenzo[b]thiophen-2-yl group, 5-fluoro-6-methylthiobenzo[b]thiophen-2-yl group, biphenyl-4-yl group, 2’-fluorobiphenyl-4-yl group, 3’-fluorobiphenyl-4-yl group, 4’-fluorobiphenyl-4-yl group, 2’,4’-difluoro-biphenyl-4-yl group, 3’,4’-difluorobiphenyl-4-yl group, 2’-chlorobiphenyl-4-yl group, 3’-chlorobiphenyl-4-yl group, 4’-chlorobiphenyl-4-yl group, 4’-chloro-2’-fluoro-
biphenyl-4-yl group, 4’-chloro-3’-fluorobiphenyl-4-yl group, 4’-hydroxybiphenyl-4-yl group, 3’-methylbiphenyl-4-yl group, 3’-ethylbiphenyl-4-yl group, 3’-trifluoromethyl-biphenyl-4-yl group, 3’-methoxybiphenyl-4-yl group, 3’-difluoromethoxybiphenyl-4-yl group, 4-(thiophen-2-yl)phenyl group, 4-(thiophen-3-yl)phenyl group, 4-(pyrazol-1-yl)-phenyl group, 4-(oxazol-2-yl)phenyl group, 4-(oxazol-4-yl)phenyl group, 4-(thiazol-2-yl)phenyl group, 4-(4-fluorothiazol-2-yl)phenyl group, 4-(4-chlorothiazol-2-yl)phenyl group, 4-(5-chlorothiazol-2-yl)phenyl group, 4-(5-methylthiazol-2-yl)phenyl group, 4-(4,5-dimethylthiazol-2-yl)phenyl group, 4-(4-trifluoromethylthiazol-2-yl)phenyl group, 4-(thiazol-4-yl)phenyl group, 4-(2-fluorothiazol-4-yl)phenyl group, 4-(2-chlorothiazol-4-yl)phenyl group, 4-(thiazol-5-yl)phenyl group, 4-(1,2,4-triazol-1-yl)phenyl group, 4-(pyridin-2-yl)phenyl group, 4-(pyridazin-3-yl)phenyl group, 4-(pyridazin-4-yl)phenyl group, 4-(pyrimidin-2-yl)phenyl group, 4-(5-hydroxypyrimidin-2-yl)phenyl group, 4-(pyrimidin-4-yl)phenyl group, 4-(pyrimidin-5-yl)phenyl group, 4-(4,5-dihydrothiazol-2-yl)phenyl group, 6-phenylpyridazin-3-yl group, 6-(thiazol-2-yl)pyridazin-3-yl group or 6-(thiazol-4-yl)pyridazin-3-yl group, and
Z represents a phenyl group, 2-fluorophenyl group, 3-fluorophenyl group, 4-fluoro-phenyl group, 3,4-difluorophenyl group, 3,5-difluorophenyl group, 3,4,5-trifluorophenyl group, 2-chlorophenyl group, 3-chlorophenyl group, 4-chlorophenyl group, 2,6-dichlorophenyl group, 4-chloro-3-fluorophenyl group, 4-chloro-3,5-difluorophenyl group, 4-bromophenyl group, 4-methylphenyl group, 3-fluoro-4-methylphenyl group, 4-ethylphenyl group, 4-ethyl-3-fluorophenyl group, 4-propylphenyl group, 4-isopropyl-phenyl group, 4-tert-butylphenyl group, 4-trifluoromethylphenyl group, 3-fluoro-4-trifluoromethylphenyl group, 4-difluoromethylphenyl group, 4-trichloromethylphenyl group, 4-dichloromethylphenyl group, 4-(2,2,2-trifluoroethyl)phenyl group, 4-(2,2,2-trichloroethyl)phenyl group, 4-methoxyphenyl group, 3-fluoro-4-methoxyphenyl group, 4-ethoxyphenyl group, 4-propoxyphenyl group, 4-isopropoxyphenyl group, 4-tert-butoxyphenyl group, 4-trifluoromethoxyphenyl group, 4-difluoromethoxyphenyl group, 4-difluoromethoxy-3-fluorophenyl group, 4-trichloromethoxyphenyl group, 4-dichloro-methoxyphenyl group, thiophen-2-yl group, thiophen-3-yl group, 5-chloro thiophen-2-yl group, 1-methyl-1H-imidazol-4-yl group, thiazol-2-yl group, pyridin-2-yl group, 5-fluoropyridin-2-yl group, 5-chloropyridin-2-yl group, 5-methylpyridin-2-yl group, 5-ethylpyridin-2-yl group, 5-trifluoromethylpyridin-2-yl group, 5-methoxypyridin-2-yl group, 5-difluoromethoxypyridin-2-yl group, pyridin-3-yl group, 6-fluoropyridin-3-yl group, 6-chloropyridin-3-yl group, 6-methylpyridin-3-yl group, 6-ethylpyridin-3-yl group, 6-trifluoromethylpyridin-3-yl group, 6-methoxypyridin-3-yl group, 6-difluoro-methoxypyridin-3-yl group, pyridin-4-yl group or pyrimidin-2-yl group.
15. The medical composition according to Claim 1, wherein R1 represents a hydrogen
atom, methyl group, ethyl group, propyl group, isopropyl group, tert-butyl group or
hexyl group,
R2 and R3 each independently represent a hydrogen atom or methyl group, Y represents a benzofuran-2-yl group, 6-fluorobenzofuran-2-yl group, 6-chlorobenzo-furan-2-yl group, 6-methoxybenzofuran-2-yl group, benzo[b]thiophen-2-yl group, 6-fluorobenzo[b]thiophen-2-yl group, 6-chlorobenzo[b]thiophen-2-yl group, 6-methoxy-benzo[b]thiophen-2-yl group, biphenyl-4-yl group, 2’-fluorobiphenyl-4-yl group, 3’-fluorobiphenyl-4-yl group, 4’-fluorobiphenyl-4-yl group, 2’-chlorobiphenyl-4-yl group, 3’-chlorobiphenyl-4-yl group, 4’-chlorobiphenyl-4-yl group, 3’-methylbiphenyl-4-yl group, 3’-trifluoromethylbiphenyl-4-yl group, 4-(thiophen-2-yl)phenyl group, 4-(thiophen-3-yl)phenyl group, 4-(pyrazol-1-yl)phenyl group, 4-(oxazol-2-yl)phenyl group, 4-(oxazol-4-yl)phenyl group, 4-(thiazol-2-yl)phenyl group, 4-(4-fluorothiazol-2-yl)phenyl group, 4-(4-chlorothiazol-2-yl)phenyl group, 4-(5-chlorothiazol-2-yl)phenyl group, 4-(5-methylthiazol-2-yl)phenyl group, 4-(4,5-dimethylthiazol-2-yl)phenyl group, 4-(4-trifluoromethylthiazol-2-yl)phenyl group, 4-(thiazol-4-yl)phenyl group, 4-(2-fluorothiazol-4-yl)phenyl group, 4-(2-chlorothiazol-4-yl)phenyl group, 4-(thiazol-5-yl)phenyl group, 4-(1,2,4-triazol-1-yl)phenyl group, 4-(pyridin-2-yl)phenyl group, 4-(pyridazin-3-yl)phenyl group, 4-(pyridazin-4-yl)phenyl group, 4-(pyrimidin-2-yl)phenyl group, 4-(pyrimidin-4-yl)phenyl group, 4-(pyrimidin-5-yl)phenyl group, 4-(4,5-dihydro-thiazol-2-yl)phenyl group or 6-phenylpyridazin-3-yl group, and Z represents a phenyl group, 2-fluorophenyl group, 3-fluorophenyl group, 4-fluoro-phenyl group, 3,4-difluorophenyl group, 3,5-difluorophenyl group, 2-chlorophenyl group, 3-chlorophenyl group, 4-chlorophenyl group, 2,6-dichlorophenyl group, 4-chloro-3-fluorophenyl group, 4-methylphenyl group, 3-fluoro-4-methylphenyl group, 4-ethylphenyl group, 4-ethyl-3-fluorophenyl group, 4-trifluoromethylphenyl group, 3-fluoro-4-trifluoromethylphenyl group, 4-methoxyphenyl group, 3-fluoro-4-methoxy-phenyl group, 4-difluoromethoxyphenyl group, 4-difluoromethoxy-3-fluorophenyl group, thiophen-2-yl group, thiophen-3-yl group, pyridin-2-yl group, 5-fluoropyridin-2-yl group, 5-chloropyridin-2-yl group, 5-methoxypyridin-2-yl group, pyridin-3-yl group, 6-fluoropyridin-3-yl group, 6-chloropyridin-3-yl group, 6-methoxypyridin-3-yl group or pyridin-4-yl group.
16. The medical composition according to Claim 1, wherein R1 represents a hydrogen
atom, methyl group, ethyl group, isopropyl group or hexyl group,
R2 and R3 each represent a hydrogen atom,
Y represents a benzofuran-2-yl group, 6-fluorobenzofuran-2-yl group, 6-chlorobenzo-
furan-2-yl group, 6-methoxybenzofuran-2-yl group, benzo[b]thiophen-2-yl group, 6-
fluorobenzo[b]thiophen-2-yl group, 6-chlorobenzo[b]thiophen-2-yl group, 6-methoxy-
benzo[b]thiophen-2-yl group, biphenyl-4-yl group, 2’-fluorobiphenyl-4-yl group, 3’-
fluorobiphenyl-4-yl group, 4’-fluorobiphenyl-4-yl group, 2’-chlorobiphenyl-4-yl group,
3’-chlorobiphenyl-4-yl group, 4’-chlorobiphenyl-4-yl group, 3’-methylbiphenyl-4-yl
group, 3’-trifluoromethylbiphenyl-4-yl group, 4-(thiophen-2-yl)phenyl group, 4-
(thiophen-3-yl)phenyl group, 4-(pyrazol-1-yl)phenyl group, 4-(oxazol-2-yl)phenyl
group, 4-(oxazol-4-yl)phenyl group, 4-(thiazol-2-yl)phenyl group, 4-(4-fluorothiazol-2-
yl)phenyl group, 4-(4-chlorothiazol-2-yl)phenyl group, 4-(5-chlorothiazol-2-yl)phenyl
group, 4-(5-methylthiazol-2-yl)phenyl group, 4-(4,5-dimethylthiazol-2-yl)phenyl group,
4-(4-trifluoromethylthiazol-2-yl)phenyl group, 4-(thiazol-4-yl)phenyl group, 4-(2-
fluorothiazol-4-yl)phenyl group, 4-(2-chlorothiazol-4-yl)phenyl group, 4-(thiazol-5-yl)-
phenyl group, 4-(1,2,4-triazol-1-yl)phenyl group, 4-(pyridin-2-yl)phenyl group, 4-
(pyridazin-3-yl)phenyl group, 4-(pyridazin-4-yl)phenyl group, 4-(pyrimidin-2-yl)phenyl
group, 4-(pyrimidin-4-yl)phenyl group, 4-(pyrimidin-5-yl)phenyl group, 4-(4,5-dihydro-
thiazol-2-yl)phenyl group or 6-phenylpyridazin-3-yl group, and
Z represents a phenyl group, 2-fluorophenyl group, 3-fluorophenyl group, 4-fluoro-phenyl group, 2-chlorophenyl group, 3-chlorophenyl group, 4-chlorophenyl group, 2,6-dichlorophenyl group, 4-methoxyphenyl group, pyridin-2-yl group or pyridin-3-yl group.
17. The medical composition according to Claim 1, wherein R1 represents a hydrogen atom, methyl group, ethyl group, isopropyl group or hexyl group, R2 and R3 each represent a hydrogen atom,
Y represents a benzofuran-2-yl group, benzo[b]thiophen-2-yl group, 6-chlorobenzo-
[b]thiophen-2-yl group, 6-methoxybenzo[b]thiophen-2-yl group, biphenyl-4-yl group,
4’-fluorobiphenyl-4-yl group, 4’-chlorobiphenyl-4-yl group, 4-(pyrazol-1-yl)phenyl
group, 4-(thiazol-2-yl)phenyl group, 4-(5-chlorothiazol-2-yl)phenyl group, 4-(5-
methylthiazol-2-yl)phenyl group, 4-(4,5-dimethylthiazol-2-yl)phenyl group, 4-(4-
trifluoromethylthiazol-2-yl)phenyl group, 4-(thiazol-4-yl)phenyl group, 4-(1,2,4-triazol-
1-yl)phenyl group, 4-(pyridin-2-yl)phenyl group, 4-(pyridazin-4-yl)phenyl group, 4-
(pyrimidin-2-yl)phenyl group, 4-(4,5-dihydrothiazol-2-yl)phenyl group or 6-phenyl-
pyridazin-3-yl group, and
Z represents a phenyl group, 2-fluorophenyl group, 3-fluorophenyl group, 4-fluoro-
phenyl group, 2-chlorophenyl group, 3-chlorophenyl group, 4-chlorophenyl group, 2,6-dichlorophenyl group, 4-methoxyphenyl group, pyridin-2-yl group or pyridin-3-yl group.
18. The medical composition according to Claim 1, wherein the pyridylaminoacetic acid compound is
{6-[(benzofuran-2-ylmethyl)(pyridin-3-ylsulfonyl)aminomethyl]pyridin-2-ylamino}-acetic acid,
{6-[(benzo[b]thiophen-2-ylmethyl)(pyridin-3-ylsulfonyl)aminomethyl]pyridin-2-yl-amino}acetic acid,
{6-[(6-chlorobenzo[b]thiophen-2-ylmethyl)(pyridin-3-ylsulfonyl)aminomethyl]pyridin-2-ylamino}acetic acid,
{6-[(6-methoxybenzo[b]thiophen-2-ylmethyl)(pyridin-3-ylsulfonyl)aminomethyl]-pyridin-2-ylamino}acetic acid,
{6-[(biphenyl-4-ylmethyl)(pyridin-2-ylsulfonyl)aminomethyl]pyridin-2-ylamino}acetic acid,
{6-[(biphenyl-4-ylmethyl)(pyridin-3-ylsulfonyl)aminomethyl]pyridin-2-ylamino}acetic acid,
{6-[(4’-fluorobiphenyl-4-ylmethyl)(pyridin-3-ylsulfonyl)aminomethyl]pyridin-2-yl-amino}acetic acid,
{6-[(4’-chlorobiphenyl-4-ylmethyl)(pyridin-3-ylsulfonyl)aminomethyl]pyridin-2-yl-amino}acetic acid,
(6-{(4-fluorobenzenesulfonyl)[4-(pyrazol-1-yl)benzyl]aminomethyl}pyridin-2-yl-amino)acetic acid,
(6-{[4-(pyrazol-1-yl)benzyl](pyridin-2-ylsulfonyl)aminomethyl}pyridin-2-ylamino)-acetic acid,
(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)-acetic acid,
isopropyl (6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)acetate,
ethyl (6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-yl-amino)acetate,
(6-{(4-fluorobenzenesulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-yl-amino)acetic acid,
(6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)-acetic acid,
(6-{(pyridin-3-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)-
acetic acid,
(6-{(pyridin-2-ylsulfonyl)[4-(4-trifluoromethylthiazol-2-yl)benzyl]aminomethyl}-
pyridin-2-ylamino)acetic acid,
(6-{(pyridin-2-ylsulfonyl)[4-(thiazol-4-yl)benzyl]aminomethyl}pyridin-2-ylamino)-
acetic acid,
(6-{[4-(pyridin-2-yl) benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)-
acetic acid,
(6-{[4-(pyridazin-4-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)-
acetic acid,
(6-{(pyridin-2-ylsulfonyl)[4-(pyrimidin-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)-
acetic acid,
(6-{[4-(4,5-dihydrothiazol-2-yl)benzyl](4-fluorobenzenesulfonyl)aminomethyl}pyridin-
2-ylamino)acetic acid,
{6-[(6-phenylpyridazin-3-ylmethyl)(pyridin-3-ylsulfonyl)aminomethyl]pyridin-2-yl-
amino} acetic acid,
hexyl (6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-yl-
amino)acetate,
(6-{[4-(5-chlorothiazol-2-yl)benzyl](pyridin-2-ylsulfonyl)aminomethyl}pyridin-2-yl-
amino)acetic acid,
(6-{[4-(5-methylthiazol-2-yl)benzyl](pyridin-2-ylsulfonyl)aminomethyl}pyridin-2-yl-
amino)acetic acid,
(6-{[4-(4,5-dimethylthiazol-2-yl)benzyl](pyridin-2-ylsulfonyl)aminomethyl}pyridin-2-
ylamino)acetic acid,
(6-{(pyridin-3-ylsulfonyl)[4-(l,2,4-triazol-l -yl) benzyl] am ino methyl} pyridin-2-yl-
amino)acetic acid,
(6-{[4-(pyrazol-l-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)-
ethyl acetate or
(6-{[4-(pyrazol-l-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)-
isopropyl acetate.
| # | Name | Date |
|---|---|---|
| 1 | 7743-CHENP-2011-AbandonedLetter.pdf | 2018-04-09 |
| 1 | Power of Authority.pdf | 2011-10-28 |
| 2 | 7743-CHENP-2011-Information under section 8(2) (MANDATORY) [29-12-2017(online)].pdf | 2017-12-29 |
| 2 | Form-5.pdf | 2011-10-28 |
| 3 | Form-3.pdf | 2011-10-28 |
| 3 | 7743-CHENP-2011-FORM 4(ii) [06-12-2017(online)].pdf | 2017-12-06 |
| 4 | Form-1.pdf | 2011-10-28 |
| 4 | Correspondence by Agent_Verified English Translation_25-09-2017.pdf | 2017-09-25 |
| 5 | 7743-CHENP-2011-Certified Copy of Priority Document (MANDATORY) [22-09-2017(online)].pdf | 2017-09-22 |
| 5 | 7743-CHENP-2011 CORRESPONDENCE OTHERS 18-11-2011.pdf | 2011-11-18 |
| 6 | 7743-CHENP-2011-FER.pdf | 2017-06-29 |
| 6 | 7743-CHENP-2011 ASSIGNMENT 18-11-2011.pdf | 2011-11-18 |
| 7 | 7743-CHENP-2011 CORRESPONDENCE OTHERS 04-02-2013.pdf | 2013-02-04 |
| 7 | 7743-CHENP-2011 FORM-3 16-03-2012.pdf | 2012-03-16 |
| 8 | 7743-CHENP-2011 FORM-1 04-02-2013.pdf | 2013-02-04 |
| 8 | 7743-CHENP-2011 CORRESPONDENCE OTHERS 16-03-2012.pdf | 2012-03-16 |
| 9 | 7743-CHENP-2011 FORM-13 04-02-2013.pdf | 2013-02-04 |
| 9 | abstract7743-CHENP-2011.jpg | 2012-11-09 |
| 10 | 7743-CHENP-2011 POWER OF ATTORNEY 04-02-2013.pdf | 2013-02-04 |
| 11 | 7743-CHENP-2011 FORM-13 04-02-2013.pdf | 2013-02-04 |
| 11 | abstract7743-CHENP-2011.jpg | 2012-11-09 |
| 12 | 7743-CHENP-2011 CORRESPONDENCE OTHERS 16-03-2012.pdf | 2012-03-16 |
| 12 | 7743-CHENP-2011 FORM-1 04-02-2013.pdf | 2013-02-04 |
| 13 | 7743-CHENP-2011 FORM-3 16-03-2012.pdf | 2012-03-16 |
| 13 | 7743-CHENP-2011 CORRESPONDENCE OTHERS 04-02-2013.pdf | 2013-02-04 |
| 14 | 7743-CHENP-2011 ASSIGNMENT 18-11-2011.pdf | 2011-11-18 |
| 14 | 7743-CHENP-2011-FER.pdf | 2017-06-29 |
| 15 | 7743-CHENP-2011 CORRESPONDENCE OTHERS 18-11-2011.pdf | 2011-11-18 |
| 15 | 7743-CHENP-2011-Certified Copy of Priority Document (MANDATORY) [22-09-2017(online)].pdf | 2017-09-22 |
| 16 | Correspondence by Agent_Verified English Translation_25-09-2017.pdf | 2017-09-25 |
| 16 | Form-1.pdf | 2011-10-28 |
| 17 | 7743-CHENP-2011-FORM 4(ii) [06-12-2017(online)].pdf | 2017-12-06 |
| 17 | Form-3.pdf | 2011-10-28 |
| 18 | 7743-CHENP-2011-Information under section 8(2) (MANDATORY) [29-12-2017(online)].pdf | 2017-12-29 |
| 18 | Form-5.pdf | 2011-10-28 |
| 19 | Power of Authority.pdf | 2011-10-28 |
| 19 | 7743-CHENP-2011-AbandonedLetter.pdf | 2018-04-09 |
| 1 | 7743chenp2011_21-06-2017.pdf |
| 1 | surechem_21-06-2017.pdf |
| 2 | 7743chenp2011_21-06-2017.pdf |
| 2 | surechem_21-06-2017.pdf |